Targets › DCXR
1 program from 1 company in 1 trial: 1 Phase 3; Oncology; next expected readout Aug 2029.
Catalyzes the NADPH-dependent reduction of several pentoses, tetroses, trioses, alpha-dicarbonyl compounds and L-xylulose. Can use both NAD and NADP as cosubstrate but shows higher activity with NADP. Participates in the uronate cycle of glucose metabolism. (UniProt, Q7Z4W1)
Open in Phaseline: the race on DCXR, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| PharmaMar | Lurbinectedin Alkylating agent that binds to DNA and causes strand breaks | DCXR | Phase 3 | Leiomyosarcoma | Aug 2029 |
Leiomyosarcoma (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.